TECHNOLOGY

The Clarimedix technology was developed utilizing a ground breaking discovery made in 2006. At that time, Dr. Robert Poyton, a University of Colorado researcher, discovered for the first time that nitric oxide (NO) was produced from mitochondrial cytochrome c oxidase under certain oxygen conditions (The Cco/NO receptor; Castello et al. 2006; Castello et al. 2008).

The Cco/NO receptor is an endogenous, intracellular, light-sensitive mitochondrial receptor that is un-related to the better-known NOS system. Clarimedix, working with Dr. Poyton and the University of Colorado then demonstrated that light of an appropriate wavelength, intensity and duration can be used to control the Cco/NO receptor – stimulating it, or inhibiting it at will, even under low oxygen conditions.

Poyton, RO and Ball, KA., Therapeutic photobiomodulation: nitric oxide and a novel function of mitochondrial cytochrome c oxidase; Discov Med. 2011 Feb;11(57):154-9.

Poyton RO, Ball KA, Castello, PR, Mitochondrial generation of free radicals and hypoxic signaling; Trends in Endocrinology and Metabolism 2009; 20(7):332-40.

Ball KA, Castello PR, Poyton RO, Low intensity light stimulates nitrite-dependent nitric oxide synthesis but not oxygen consumption by cytochrome c oxidase: Implications for phototherapy; J Photochem Photobiol B. 2011 Mar 2;102(3):182-91.